Edition:
India

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

0.49USD
24 Apr 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.49
Open
$0.50
Day's High
$0.52
Day's Low
$0.49
Volume
10,097
Avg. Vol
43,691
52-wk High
$1.57
52-wk Low
$0.31

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Says It Has Put Its Hope-2 Clinical Trial On A Voluntary Dosing Hold
Wednesday, 26 Dec 2018 

Dec 26 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ON DEC 21, CO ANNOUNCED THAT IT HAS PUT ITS HOPE-2 CLINICAL TRIAL ON A VOLUNTARY DOSING HOLD - SEC FILING.CAPRICOR THERAPEUTICS - HOPE-2 CLINICAL TRIAL ON VOLUNTARY DOSING HOLD PENDING ONGOING SAFETY REVIEW DUE TO SEVERE ALLERGIC REACTION.CAPRICOR - TRIAL'S ONGOING SAFETY REVIEW DUE TO SEVERE ALLERGIC REACTION OCCURRED DURING PATIENT INFUSION OF BLINDED INVESTIGATIONAL PRODUCT.CAPRICOR - PATIENT RESPONDED WELL TO MEDICAL TREATMENT AND IS CURRENTLY ASYMPTOMATIC.CAPRICOR THERAPEUTICS - HAS NOTIFIED FDA ABOUT ISSUE AND IS WORKING CLOSELY WITH THE FDA ON A MITIGATION PLAN.  Full Article

Capricor Therapeutics Q3 Loss Per Share $0.14
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.14.AS OF SEPTEMBER 30, 2018, COMPANY'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED APPROXIMATELY $10.4 MILLION.CAPRICOR THERAPEUTICS - BELIEVES CURRENT FINANCIAL RESOURCES SHOULD BE SUFFICIENT TO FUND OPERATIONS AND MEET FINANCIAL OBLIGATIONS INTO Q2 OF 2019.  Full Article

Capricor Q4 Earnings Per Share $0.42
Thursday, 15 Mar 2018 

March 14 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.42.CAPRICOR THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OTHERSTHROUGH Q4 OF 2018.  Full Article

Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation
Monday, 5 Feb 2018 

Feb 5 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at WMS International Congress
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Capricor Therapeutics Inc : :Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at World Muscle Society International Congress.Capricor Therapeutics Inc - ‍treatment with CAP-1002 was generally safe and well-tolerated over initial six-month follow-up period of hope trial​.  Full Article

Capricor Therapeutics Q2 loss per share $0.16
Friday, 11 Aug 2017 

Aug 10 (Reuters) - Capricor Therapeutics Inc :Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.16.Capricor Therapeutics Inc - announced statistically-significant improvements in skeletal and cardiac muscle function in patients treated with CAP-1002.Capricor Therapeutics Inc - plans to commence clinical trial of I.V. CAP-1002 in Duchenne Muscular Dystrophy in the fourth quarter.  Full Article

U.S. drug developer Capricor places Duchenne drug trial on hold

Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.